Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

732 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 vaccination and phase 1 cancer clinical trials.
Yap TA, Siu LL, Calvo E, Lolkema MP, LoRusso PM, Soria JC, Plummer R, de Bono JS, Tabernero J, Banerji U. Yap TA, et al. Among authors: soria jc. Lancet Oncol. 2021 Mar;22(3):298-301. doi: 10.1016/S1470-2045(21)00017-6. Epub 2021 Feb 8. Lancet Oncol. 2021. PMID: 33571468 Free PMC article. No abstract available.
Chemoprevention of lung cancer.
Soria JC, Kim ES, Fayette J, Lantuejoul S, Deutsch E, Hong WK. Soria JC, et al. Lancet Oncol. 2003 Nov;4(11):659-69. doi: 10.1016/s1470-2045(03)01244-0. Lancet Oncol. 2003. PMID: 14602246 Review.
Toward a better dialogue between neuro-oncologists and phase I investigators.
Massard C, Sandhu S, Blanco M, Papadatos-Pastos D, Carden C, De Bono J, Saran F, Molife LR, Kaye SB, Soria JC, Banerji U. Massard C, et al. Among authors: soria jc. J Clin Oncol. 2012 Feb 10;30(5):562-3; author reply 563-4. doi: 10.1200/JCO.2011.39.8347. Epub 2012 Jan 3. J Clin Oncol. 2012. PMID: 22215743 No abstract available.
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.
Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB. Olmos D, et al. Among authors: soria jc. J Clin Oncol. 2012 Mar 20;30(9):996-1004. doi: 10.1200/JCO.2010.34.5074. Epub 2012 Feb 21. J Clin Oncol. 2012. PMID: 22355064
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Martinez-Garcia M, Banerji U, Albanell J, Bahleda R, Dolly S, Kraeber-Bodéré F, Rojo F, Routier E, Guarin E, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Soria JC. Martinez-Garcia M, et al. Among authors: soria jc. Clin Cancer Res. 2012 Sep 1;18(17):4806-19. doi: 10.1158/1078-0432.CCR-12-0742. Epub 2012 Jul 3. Clin Cancer Res. 2012. PMID: 22761467 Clinical Trial.
732 results